You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股收評:三大指數齊跌,醫藥地產股表現突出

三大指數齊跌,滬指微跌0.02%報3167點,深成指跌0.56%報11295點,創業板指跌1.06%報2373點。兩市3593股下跌,1323股上漲,成交額7600億,北上資金臨近收盤快速流入,全天淨買入43.6億。兩市繼續調整,成交量維持在低位,市場情緒依舊偏謹慎。

盤面上,醫藥、地產鏈股早盤衝高後進入橫盤整理,細分熊去氧膽酸概念暴漲,新冠藥、仿製藥、疫苗等概念表現強勁,中國醫藥、眾生藥業等多股漲停,新華製藥經過昨日短暫調整後再度封板,錄得10天8板;地產、銀行、保險板塊漲幅靠前,蘇州高新、陸家嘴等股漲停。昨天表現強勁的汽配、信創、芯片概念跌幅靠前,光伏、鋰電池概念股普遍下跌。

具體來看:

Chiplet概念股下挫,麥格米特、路維光電跌超6%,高測股份、京泉華、光莆股份跌超5%,海能實業、聯動科技等跟跌。

消息面上,美國商務部宣佈將長江存儲、寒武紀等36家中國企業列入實體清單。

光伏股走弱,綠康生化、賽伍科技跌超9%,鑫鉑股份跌超8%,格利爾、上能電器跌超7%,宇晶股份、寶馨科技等跟跌。

據近日PVInfoLink發佈的最新光伏供應鏈價格顯示,本週光伏產業鏈價格迎來全線下跌。其中,硅片價格跌幅最大,最小跌幅至6.4%,最大跌幅達11.6%;電池片各尺寸均價跌幅在5.8%-8.4%;多晶緻密料均價下跌3.8%。東方證券發研報指,國內光伏產業鏈整體呈現價格下跌態勢,由於海外過節以及臨近年末,出口組件需求有所下滑,而國內組件去庫搶裝進度尚未加速,使得庫存量增加從而導致上游硅片,電池片價格難以維持,預計價格下跌的行情可能會持續較長的時間。

汽車股跌幅居前,眾泰汽車、塞力斯跌超5%,中通客車、亞星客車、江淮汽車跌超3%,安凱汽車、中集車輛等跟跌。

新冠藥概念股再度走高,熊去氧膽酸方向領漲,中國醫藥2連板,廣生堂20cm漲停,上海凱寶漲超16%,新華製藥、眾生藥業漲停,九典制藥漲超9%,賽升藥業、復星醫藥等紛紛走強。

消息面上,中國醫藥與輝瑞公司簽訂協議,將在協議期內負責輝瑞公司新冠病毒治療藥物奈瑪特韋片/利托那韋片在中國大陸市場的進口和經銷。協議簽署、生效日是北京時間2022年12月14日,直至2023年11月30日止。

內房股表現活躍,格力地產、陸家嘴、蘇州高新漲停,萬家企業漲超5%,華僑城A、中交地產漲超4%,華髮股份、信達地產等跟漲。

消息面上,國務院副總理劉鶴強調,房地產是國民經濟的支柱產業,針對當前出現的下行風險,已出台一些政策,正在考慮新的舉措,努力改善行業的資產負債狀況,引導市場預期和信心回暖。平安證券指出,政策風向正在加速轉變,需求端政策寬鬆可期,建議積極把握地產產業鏈行情。

個股異動

陸家嘴復牌一字板漲停,現報11.01元創近7個月新高價,總市值444億元。公司昨晚發佈公吿,擬募資購買昌邑公司、耀龍公司和企榮公司股權。通過本次交易,陸家嘴集團將位於陸家嘴金融貿易區和前灘國際商務區的優質資產注入上市公司,有利於上市公司更深度地參與陸家嘴金融城東擴及前灘國際商務區的開發建設和運營。

北向資金方面,北上資金淨流入82.85億元,其實滬股通淨流入59.9億元,深股通淨流入22.95億元。

展望後市,國盛證券指出,在國內基本面復甦趨勢不改,宏觀資金面仍充裕,在房住不炒的大背景下,“資產荒”對A股估值形成有利支撐,考慮到當前市場呈現出較強的中期反彈特徵,A股年底也可能是孕育後續大級別行情的配置窗口,當前建議保持價值略小於成長的均衡配置。操作上,在市場有效向上突破之前仍要控制好總體倉位適宜低吸,消費復甦有望成為驅動市場運行的主要邏輯,關注邊際改善的醫療器械、軍工、食品消費等板塊和具有較高估值性價比的金融和地產鏈等權重方向。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account